Study on Fluids Associated to Lung Cancer
- Conditions
- Lung Cancer
- Registration Number
- NCT02853006
- Lead Sponsor
- University Hospital, Grenoble
- Brief Summary
The diagnosis of lung cancer is the first cause of cancer deaths for man and woman. It requires invasive procedures (at least endoscopy, transthoracic puncture, or surgery).
This study is about the set up of an innovative test for lung cancer prognosis, based on biopsies and surgical material : LungCancerTest, with the creation of a start-up in progress.
The main goal of this study is to approve the diagnostic value of the molecular signature of the 26 genes (LungCancerTest) revealed in blood and respiratory fluids among patients with lung cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 31
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Quantification of : DNA Half a day From plasma or respiratory fluids, with Qiagen QIAamp MinElute Virus Spin kit.
Picogreen technique (fluorimétrie) with the device Qubit 2.0 Characterization of DNA by migration on revealed agarose gel in presence of ethidium bromide
Study of DNA (mutation, reassortment) with New Generation Sequencing materiel.Quantification of : RNA Half a day From plasma or respiratory fluids, with Qiagen QIAamp MinElute Virus Spin kit.
Picogreen technique (fluorimétrie) with the device Qubit 2.0 Characterization of RNA with an Agilent chip
Study of RNA (LungCancerTest) with PCR-Array prototype to show the expression of the molecular signature (Cancer Testis genes).
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
UniversityHospitalGrenoble
🇫🇷La Tronche, France
UniversityHospitalGrenoble🇫🇷La Tronche, France